Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
- Imetelstat is a cancer treatment drug that may slow or stop tumor growth. It may also prevent tumors from spreading to other parts of the body. Researchers want to see if it can be a safe and effective treatment for children who have solid tumors or lymphoma that have not responded to other treatments.
- To see if imetelstat is a safe and effective treatment for children who have solid tumors or lymphoma that have not responded to other treatments.
- Children and adolescents between 1 and 21 years of age who have solid tumors or lymphoma that have not responded to other treatments.
- Participants will be screened with a physical exam, medical history, and imaging studies. Blood and urine samples will also be collected.
- Participants will receive imetelstat on the first and eighth day of a 21-day cycle of treatment.
- Treatment will be monitored with frequent blood tests and imaging studies. Tumor biopsies may also be performed.
- Participants will keep taking the study drugs for up to a total of 18 cycles as long as the disease does not progress and there are no severe side effects....
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas|
- Estimate the maximum tolerated dose (MTD) of imetelstat given as a 2-hour IV infusion on D1 and D8 every 21 days.
- Define the toxicities and characterize pharmacokinetics
- To define antitumor effects and to assess the biological activity by assessing telomerase activity, telomere length, hTERT protein, hTERT mRNA and hTR levels; hTERT expression and protein, telomere length, hTERT mRNAS and hTR levels in tumor.
|Study Start Date:||March 2012|
|Study Completion Date:||October 2012|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01568632
|Principal Investigator:||William L Dahut, M.D.||National Cancer Institute (NCI)|